Drugmaker Teva Pharmaceutical Industries Ltd. said Wednesday a U.S. Court backed a ruling that overturned a patent behind Bayer Schering's birth control pill Yasmin.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Teva said the U.S. Court of Appeals for the Federal Circuit supported an earlier ruling made by the U.S. District Court for the District of New Jersey. The ruling allows Teva to launch its own generic version of the drug rather than licensing it from Bayer Schering.
Under terms of an agreement reached in June 2008, Teva's Barr Pharmaceutical subsidiary buys a generic version of Yasmin from Bayer Schering and sells it under the name Ocella. Teva said Ocella was launched in July 2008, and sales for that year were $170.2 million.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
